digital health virtual network
information, learning and connections in Digital Health
The Digital Health Virtual Network (DHV-NET) provides opportunities for learning and interaction coupled with high quality information.
We help senior decision makers to develop a broad understanding of digital health and in-depth knowledge in areas of special interest.
DHV-NET provides an efficient, novel and engaging way to maintain an up to date understanding and network in this broad and fast-moving field.
Get involved by registering your interest in our invite-only, monthly networking events link below; a unique experience in post-covid networking. These events connect the digital health ecosystem around key themes, delivering high quality content from leaders in the field combined with rapid introductions and thoughtful breakouts.
Find out more. Contact:
where genomics meets digital health
please register your interest on the linkedin event site using the link above. PLEASE NOTE We typically have several hundred expressions of interest but CAN only ACCOMMODATE A GROUP SIZE OF 50 maximum. THESE are curated, invite-only, events DESIGNED for senior decision makers (typically C-suite digital health companies, investors, execs from multinationals, NGOs and HCPs). subsequent to registrations of interest, we share Links to the ticketing site with those who fall within these categories.
Joanne M. Hackett is the Head of Genomic and Precision Medicine at IQVIA and previously was the Chief Commercial Officer at Genomics England.
Dr Hackett is a clinical academic, entrepreneur, investor, and a strategic, creative visionair with global experience spanning successful start-ups to Fortune 500 companies. Aside from her curious passion for life and positivity, Joanne is known for building innovation, driving personalised medicine and leading through fast paced, complex changing ecosystems and integrations. Joanne's goal is to contribute in bringing the world novel, cost effective and simple health care solutions, and she is particularly keen on building the case for prevention, open science and citizen genomics. She has extensive global experience across academic, business and clinical institutions, and enjoys sharing her experiences with the Boards she sits on as well as companies she provides strategic advice to.
Joanne has been publicly recognised for her relentless pursuit of revolutionising healthcare and has recently been named one of the top six Influential Leaders in Healthcare by CIO Look, the Accenture Life Science Leader of the year 2019, Freshfields Top 100 Most Influential Women 2019, One HealthTech 2018 Top 70 Women in the NHS, Pharmaceutical Market Europe’s 2018 30 women leaders in UK healthcare and BioBeat 2017 Top 50 Women in Biotech Award. Joanne believes in human courage and perseverance against the odds, and demonstrates that positive change, whether in a company or in one’s personal life, can be carved out from even the greatest of trials. As a believer of ‘health = wealth’, Joanne is an internationally known yoga instructor.
Fabian Mohr is a oncology scientist turned venture capitalist at one of EUs most active early stage investors High-Tech Gründerfonds (HTGF) in Germany. He has a background in molecular medicine and did his PhD in hemato-oncology at the International Graduate School of Molecular Medicine at University of Ulm. He published several papers about genes involved in epigenetics in normal and malignant hematopoiesis involving next-generation sequencing and algorithm based analytics.
After his PhD, he joined Accenture Strategy in Germany in their Technology practice as a consultant and project lead for clients in big pharma and medtech. He focused mainly on innovation topics, data-driven business and IT M&A. As part of his engagement, he was involved in thought leadership in data strategy and digital patient services.
In his current role as Senior Investment Manager at HTGF, he represents the fund in 10 companies and holds four board seats. Within HTGF he focusses on Digital Health and has invested into two companies which use genomics as part of their value proposition.
Calum MacRae, MD, PhD, is Professor of Medicine at Harvard Medical School, an Associate Member at the Broad Institute of Harvard and MIT and a Principal Faculty Member at the Harvard Stem Cell Institute. He graduated from Edinburgh Medical School and trained in Medicine and Cardiology in Edinburgh and London. He obtained his PhD from the University of London and undertook postdoctoral work in human genetics and developmental biology at Harvard Medical School. He subsequently completed additional training in Medicine at Brigham and Women’s Hospital and Cardiology at Massachusetts General Hospital where he remained on faculty, latterly directing the Cardiology Fellowship Program before becoming Chief of Cardiovascular Medicine at Brigham and Women’s Hospital in 2014.
Dr. MacRae moved to his current role, where he directs a multispecialty innovation group, in 2018. He is also the Director of the One Brave Idea, a program to transform translational biomedicine that is funded jointly by the American Heart Association, Verily Life Sciences and AstraZeneca with pillar support from Quest Diagnostics. He is the principal investigator of the Apple Heart & Movement study and also directs an NIH-funded basic science group.
Dr. MacRae’s work includes the human genetics of disease, developmental biology, and drug discovery. He has a longstanding interest in systems modeling of disease biology and has exploited novel animal models and machine learning to accelerate this work and to undertake parallel drug discovery. He also has a significant effort focused on systematic approaches to the discovery of new human phenotypes and the role of disruptive innovation in refashioning the clinical-translational interface. His major clinical focus is genetics and he co-directs the Genomic Medicine Program at Brigham and Women’s Hospital and is a clinical lead in the Harvard Undiagnosed Diseases Center.